CLDX - Celldex Therapeutics, Inc.
29.43
0.070 0.238%
Share volume: 673,265
Last Updated: 03-06-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.03%
PREVIOUS CLOSE
CHG
CHG%
$29.36
0.07
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-06-2024 | 08-08-2024 | 11-06-2024 | 02-27-2025 | 05-08-2025 | 08-07-2025 | 11-10-2025 | 02-25-2026 | |
| Assets | |||||||||
| Total Assets | 868.847 M | 845.586 M | 823.179 M | 792.340 M | 739.471 M | 692.407 M | 648.439 M | 582.983 M | |
| Current Assets | 835.324 M | 811.975 M | 778.842 M | 747.159 M | 693.757 M | 648.404 M | 604.339 M | 534.664 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 708.769 M | 759.578 M | 719.600 M | 696.925 M | 656.155 M | 607.293 M | 547.186 M | 489.702 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 115.077 M | 42.739 M | 36.399 M | 28.356 M | 17.136 M | 23.044 M | 36.037 M | 28.871 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 4.061 M | 3.864 M | 4.230 M | 4.346 M | 4.601 M | 4.392 M | 4.829 M | 5.334 M | |
| Other Assets | 29.462 M | 29.747 M | 40.107 M | 40.835 M | 41.113 M | 39.611 M | 39.271 M | 42.985 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 868.847 M | 845.586 M | 823.179 M | 792.340 M | 739.471 M | 692.407 M | 648.439 M | 582.983 M | |
| Total liabilities | 30.234 M | 31.927 M | 37.274 M | 45.335 M | 36.490 M | 37.001 M | 50.076 M | 55.818 M | |
| Total current liabilities | 26.291 M | 27.658 M | 32.093 M | 39.501 M | 32.018 M | 32.963 M | 46.465 M | 50.991 M | |
| Accounts Payable | 3.234 M | 3.802 M | 1.114 M | 3.265 M | 3.410 M | 2.073 M | 4.267 M | 1.180 M | |
| Other liabilities | 3.943 M | 4.269 M | 5.181 M | 5.834 M | 4.472 M | 4.038 M | 3.611 M | 4.827 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 3.943 M | 4.269 M | 5.181 M | 5.834 M | 4.472 M | 4.038 M | 3.611 M | 4.827 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 838.613 M | 813.659 M | 785.905 M | 747.005 M | 702.981 M | 655.406 M | 598.363 M | 527.165 M | |
| Common stock | 2.267 B | 2.278 B | 2.289 B | 2.299 B | 2.308 B | 2.318 B | 2.327 B | 2.338 B | |
| Retained earnings | -1.430 B | -1.466 B | -1.508 B | -1.555 B | -1.609 B | -1.666 B | -1.733 B | -1.814 B |